Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Amino Acid Restriction Triggers Angiogenesis via GCN2/ATF4 Regulation of VEGF and H2S Production.

Longchamp A, Mirabella T, Arduini A, MacArthur MR, Das A, Treviño-Villarreal JH, Hine C, Ben-Sahra I, Knudsen NH, Brace LE, Reynolds J, Mejia P, Tao M, Sharma G, Wang R, Corpataux JM, Haefliger JA, Ahn KH, Lee CH, Manning BD, Sinclair DA, Chen CS, Ozaki CK, Mitchell JR.

Cell. 2018 Mar 22;173(1):117-129.e14. doi: 10.1016/j.cell.2018.03.001.

PMID:
29570992
2.

Corrigendum: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.

Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M, Tomas-Cortazar J, Jimenez J, Torres I, Quang P, Ximenez-Embun P, Bago R, Ugalde-Olano A, Loizaga-Iriarte A, Lacasa-Viscasillas I, Unda M, Torrano V, Cabrera D, van Liempd SM, Cendon Y, Castro E, Murray S, Revandkar A, Alimonti A, Zhang Y, Barnett A, Lein G, Pirman D, Cortazar AR, Arreal L, Prudkin L, Astobiza I, Valcarcel-Jimenez L, Zuñiga-García P, Fernandez-Dominguez I, Piva M, Caro-Maldonado A, Sánchez-Mosquera P, Castillo-Martín M, Serra V, Beraza N, Gentilella A, Thomas G, Azkargorta M, Elortza F, Farràs R, Olmos D, Efeyan A, Anguita J, Muñoz J, Falcón-Pérez JM, Barrio R, Macarulla T, Mato JM, Martinez-Chantar ML, Cordon-Cardo C, Aransay AM, Marks K, Baselga J, Tabernero J, Nuciforo P, Manning BD, Marjon K, Carracedo A.

Nature. 2018 Feb 22;554(7693):554. doi: 10.1038/nature25470. Epub 2018 Jan 17.

PMID:
29342137
3.

Improved detection of synthetic lethal interactions in Drosophila cells using variable dose analysis (VDA).

Housden BE, Li Z, Kelley C, Wang Y, Hu Y, Valvezan AJ, Manning BD, Perrimon N.

Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):E10755-E10762. doi: 10.1073/pnas.1713362114. Epub 2017 Nov 28.

4.

mTORC1 suppresses PIM3 expression via miR-33 encoded by the SREBP loci.

Kelsey I, Zbinden M, Byles V, Torrence M, Manning BD.

Sci Rep. 2017 Nov 23;7(1):16112. doi: 10.1038/s41598-017-16398-y.

5.

The mTORC1 Signaling Network Senses Changes in Cellular Purine Nucleotide Levels.

Hoxhaj G, Hughes-Hallett J, Timson RC, Ilagan E, Yuan M, Asara JM, Ben-Sahra I, Manning BD.

Cell Rep. 2017 Oct 31;21(5):1331-1346. doi: 10.1016/j.celrep.2017.10.029.

6.

mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability.

Valvezan AJ, Turner M, Belaid A, Lam HC, Miller SK, McNamara MC, Baglini C, Housden BE, Perrimon N, Kwiatkowski DJ, Asara JM, Henske EP, Manning BD.

Cancer Cell. 2017 Nov 13;32(5):624-638.e5. doi: 10.1016/j.ccell.2017.09.013. Epub 2017 Oct 19.

PMID:
29056426
7.

Game of TOR - The Target of Rapamycin Rules Four Kingdoms.

Manning BD.

N Engl J Med. 2017 Sep 28;377(13):1297-9. doi: 10.1056/NEJMcibr1709384. Epub 2017 Sep 5. No abstract available.

PMID:
28874074
8.

Corrigendum: Splicing factor 1 modulates dietary restriction and TORC1 pathway longevity in C. elegans.

Heintz C, Doktor TK, Lanjuin A, Escoubas CC, Zhang Y, Weir HJ, Dutta S, Silva-García CG, Bruun GH, Morantte I, Hoxhaj G, Manning BD, Andresen BS, Mair WB.

Nature. 2017 Jul 27;547(7664):476. doi: 10.1038/nature23313. Epub 2017 Jul 12.

PMID:
28700577
9.

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.

Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M, Tomas-Cortazar J, Jimenez J, Torres I, Quang P, Ximenez-Embun P, Bago R, Ugalde-Olano A, Loizaga-Iriarte A, Lacasa-Viscasillas I, Unda M, Torrano V, Cabrera D, van Liempd SM, Cendon Y, Castro E, Murray S, Revandkar A, Alimonti A, Zhang Y, Barnett A, Lein G, Pirman D, Cortazar AR, Arreal L, Prudkin L, Astobiza I, Valcarcel-Jimenez L, Zuñiga-García P, Fernandez-Dominguez I, Piva M, Caro-Maldonado A, Sánchez-Mosquera P, Castillo-Martín M, Serra V, Beraza N, Gentilella A, Thomas G, Azkargorta M, Elortza F, Farràs R, Olmos D, Efeyan A, Anguita J, Muñoz J, Falcón-Pérez JM, Barrio R, Macarulla T, Mato JM, Martinez-Chantar ML, Cordon-Cardo C, Aransay AM, Marks K, Baselga J, Tabernero J, Nuciforo P, Manning BD, Marjon K, Carracedo A.

Nature. 2017 Jul 6;547(7661):109-113. doi: 10.1038/nature22964. Epub 2017 Jun 28. Erratum in: Nature. 2018 Jan 17;:.

10.

A relative quantitative positive/negative ion switching method for untargeted lipidomics via high resolution LC-MS/MS from any biological source.

Breitkopf SB, Ricoult SJH, Yuan M, Xu Y, Peake DA, Manning BD, Asara JM.

Metabolomics. 2017 Mar;13(3). pii: 30. doi: 10.1007/s11306-016-1157-8. Epub 2017 Feb 7.

11.

AKT/PKB Signaling: Navigating the Network.

Manning BD, Toker A.

Cell. 2017 Apr 20;169(3):381-405. doi: 10.1016/j.cell.2017.04.001. Review.

12.

mTORC1 signaling and the metabolic control of cell growth.

Ben-Sahra I, Manning BD.

Curr Opin Cell Biol. 2017 Apr;45:72-82. doi: 10.1016/j.ceb.2017.02.012. Epub 2017 Apr 12. Review.

13.

Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex.

Howell JJ, Hellberg K, Turner M, Talbott G, Kolar MJ, Ross DS, Hoxhaj G, Saghatelian A, Shaw RJ, Manning BD.

Cell Metab. 2017 Feb 7;25(2):463-471. doi: 10.1016/j.cmet.2016.12.009. Epub 2017 Jan 12.

14.

Splicing factor 1 modulates dietary restriction and TORC1 pathway longevity in C. elegans.

Heintz C, Doktor TK, Lanjuin A, Escoubas C, Zhang Y, Weir HJ, Dutta S, Silva-García CG, Bruun GH, Morantte I, Hoxhaj G, Manning BD, Andresen BS, Mair WB.

Nature. 2017 Jan 5;541(7635):102-106. doi: 10.1038/nature20789. Epub 2016 Dec 5. Erratum in: Nature. 2017 Jul 27;547(7664):476.

15.

Emerging role of mTOR in the response to cancer therapeutics.

Ilagan E, Manning BD.

Trends Cancer. 2016 May;2(5):241-251.

16.

Sterol Regulatory Element Binding Protein Regulates the Expression and Metabolic Functions of Wild-Type and Oncogenic IDH1.

Ricoult SJ, Dibble CC, Asara JM, Manning BD.

Mol Cell Biol. 2016 Aug 26;36(18):2384-95. doi: 10.1128/MCB.00163-16. Print 2016 Sep 15.

17.

Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference.

Sahin M, Henske EP, Manning BD, Ess KC, Bissler JJ, Klann E, Kwiatkowski DJ, Roberds SL, Silva AJ, Hillaire-Clarke CS, Young LR, Zervas M, Mamounas LA; Tuberous Sclerosis Complex Working Group to Update the Research Plan.

Pediatr Neurol. 2016 Jul;60:1-12. doi: 10.1016/j.pediatrneurol.2016.03.015. Epub 2016 Apr 2.

18.

CASTORing New Light on Amino Acid Sensing.

Hallett JEH, Manning BD.

Cell. 2016 Mar 24;165(1):15-17. doi: 10.1016/j.cell.2016.03.002.

19.

mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle.

Ben-Sahra I, Hoxhaj G, Ricoult SJH, Asara JM, Manning BD.

Science. 2016 Feb 12;351(6274):728-733. doi: 10.1126/science.aad0489.

20.

Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation.

Covarrubias AJ, Aksoylar HI, Yu J, Snyder NW, Worth AJ, Iyer SS, Wang J, Ben-Sahra I, Byles V, Polynne-Stapornkul T, Espinosa EC, Lamming D, Manning BD, Zhang Y, Blair IA, Horng T.

Elife. 2016 Feb 19;5. pii: e11612. doi: 10.7554/eLife.11612.

21.

Zhang & Manning reply.

Zhang Y, Manning BD.

Nature. 2016 Jan 21;529(7586):E2-3. doi: 10.1038/nature16473. No abstract available.

22.

Identification of potential drug targets for tuberous sclerosis complex by synthetic screens combining CRISPR-based knockouts with RNAi.

Housden BE, Valvezan AJ, Kelley C, Sopko R, Hu Y, Roesel C, Lin S, Buckner M, Tao R, Yilmazel B, Mohr SE, Manning BD, Perrimon N.

Sci Signal. 2015 Sep 8;8(393):rs9. doi: 10.1126/scisignal.aab3729.

23.

Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP.

Ricoult SJ, Yecies JL, Ben-Sahra I, Manning BD.

Oncogene. 2016 Mar 10;35(10):1250-60. doi: 10.1038/onc.2015.179. Epub 2015 Jun 1.

24.

mTORC1 signaling activates NRF1 to increase cellular proteasome levels.

Zhang Y, Manning BD.

Cell Cycle. 2015;14(13):2011-7. doi: 10.1080/15384101.2015.1044188. Epub 2015 May 27. Review.

25.

Tuberous sclerosis complex 2 loss increases lysophosphatidylcholine synthesis in lymphangioleiomyomatosis.

Priolo C, Ricoult SJ, Khabibullin D, Filippakis H, Yu J, Manning BD, Clish C, Henske EP.

Am J Respir Cell Mol Biol. 2015 Jul;53(1):33-41. doi: 10.1165/rcmb.2014-0379RC.

26.

Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo.

Dowdle WE, Nyfeler B, Nagel J, Elling RA, Liu S, Triantafellow E, Menon S, Wang Z, Honda A, Pardee G, Cantwell J, Luu C, Cornella-Taracido I, Harrington E, Fekkes P, Lei H, Fang Q, Digan ME, Burdick D, Powers AF, Helliwell SB, D'Aquin S, Bastien J, Wang H, Wiederschain D, Kuerth J, Bergman P, Schwalb D, Thomas J, Ugwonali S, Harbinski F, Tallarico J, Wilson CJ, Myer VE, Porter JA, Bussiere DE, Finan PM, Labow MA, Mao X, Hamann LG, Manning BD, Valdez RA, Nicholson T, Schirle M, Knapp MS, Keaney EP, Murphy LO.

Nat Cell Biol. 2014 Nov;16(11):1069-79. doi: 10.1038/ncb3053. Epub 2014 Oct 19.

PMID:
25327288
27.

ZBTB7A acts as a tumor suppressor through the transcriptional repression of glycolysis.

Liu XS, Haines JE, Mehanna EK, Genet MD, Ben-Sahra I, Asara JM, Manning BD, Yuan ZM.

Genes Dev. 2014 Sep 1;28(17):1917-28. doi: 10.1101/gad.245910.114.

28.

Molecular basis of giant cells in tuberous sclerosis complex.

Kwiatkowski DJ, Manning BD.

N Engl J Med. 2014 Aug 21;371(8):778-80. doi: 10.1056/NEJMcibr1406613. No abstract available.

PMID:
25140966
29.

The TSC complex is required for the benefits of dietary protein restriction on stress resistance in vivo.

Harputlugil E, Hine C, Vargas D, Robertson L, Manning BD, Mitchell JR.

Cell Rep. 2014 Aug 21;8(4):1160-70. doi: 10.1016/j.celrep.2014.07.018. Epub 2014 Aug 14.

30.

Coordinated regulation of protein synthesis and degradation by mTORC1.

Zhang Y, Nicholatos J, Dreier JR, Ricoult SJ, Widenmaier SB, Hotamisligil GS, Kwiatkowski DJ, Manning BD.

Nature. 2014 Sep 18;513(7518):440-3. doi: 10.1038/nature13492. Epub 2014 Jul 13.

31.

Low-dose radiation exposure induces a HIF-1-mediated adaptive and protective metabolic response.

Lall R, Ganapathy S, Yang M, Xiao S, Xu T, Su H, Shadfan M, Asara JM, Ha CS, Ben-Sahra I, Manning BD, Little JB, Yuan ZM.

Cell Death Differ. 2014 May;21(5):836-44. doi: 10.1038/cdd.2014.24. Epub 2014 Feb 28.

32.

Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome.

Menon S, Dibble CC, Talbott G, Hoxhaj G, Valvezan AJ, Takahashi H, Cantley LC, Manning BD.

Cell. 2014 Feb 13;156(4):771-85. doi: 10.1016/j.cell.2013.11.049.

33.

The TSC-mTOR pathway regulates macrophage polarization.

Byles V, Covarrubias AJ, Ben-Sahra I, Lamming DW, Sabatini DM, Manning BD, Horng T.

Nat Commun. 2013;4:2834. doi: 10.1038/ncomms3834.

34.

Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis.

Liu P, Gan W, Inuzuka H, Lazorchak AS, Gao D, Arojo O, Liu D, Wan L, Zhai B, Yu Y, Yuan M, Kim BM, Shaik S, Menon S, Gygi SP, Lee TH, Asara JM, Manning BD, Blenis J, Su B, Wei W.

Nat Cell Biol. 2013 Nov;15(11):1340-50. doi: 10.1038/ncb2860. Epub 2013 Oct 27.

35.

mTORC1 status dictates tumor response to targeted therapeutics.

Kelsey I, Manning BD.

Sci Signal. 2013 Sep 24;6(294):pe31. doi: 10.1126/scisignal.2004632. Review.

PMID:
24065143
36.

Phosphatidylcholine transfer protein interacts with thioesterase superfamily member 2 to attenuate insulin signaling.

Ersoy BA, Tarun A, D'Aquino K, Hancer NJ, Ukomadu C, White MF, Michel T, Manning BD, Cohen DE.

Sci Signal. 2013 Jul 30;6(286):ra64. doi: 10.1126/scisignal.2004111.

37.

A growing role for mTOR in promoting anabolic metabolism.

Howell JJ, Ricoult SJ, Ben-Sahra I, Manning BD.

Biochem Soc Trans. 2013 Aug;41(4):906-12. doi: 10.1042/BST20130041. Review.

PMID:
23863154
38.

Cell signalling: nutrient sensing lost in cancer.

Menon S, Manning BD.

Nature. 2013 Jun 27;498(7455):444-5. doi: 10.1038/498444a. No abstract available.

PMID:
23803840
39.

Adaptation to starvation: translating a matter of life or death.

Manning BD.

Cancer Cell. 2013 Jun 10;23(6):713-5. doi: 10.1016/j.ccr.2013.05.012.

40.

Signal integration by mTORC1 coordinates nutrient input with biosynthetic output.

Dibble CC, Manning BD.

Nat Cell Biol. 2013 Jun;15(6):555-64. doi: 10.1038/ncb2763. Review.

41.

Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.

Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, Driggers EM, Zhang J, Bailey ST, Sharpless NE, Hayes DN, Patel NM, Janne PA, Bardeesy N, Engelman JA, Manning BD, Shaw RJ, Asara JM, Scully R, Kimmelman A, Byers LA, Gibbons DL, Wistuba II, Heymach JV, Kwiatkowski DJ, Kim WY, Kung AL, Gray NS, Root DE, Cantley LC, Wong KK.

Cancer Discov. 2013 Aug;3(8):870-9. doi: 10.1158/2159-8290.CD-13-0015. Epub 2013 May 28.

42.

Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1.

Ben-Sahra I, Howell JJ, Asara JM, Manning BD.

Science. 2013 Mar 15;339(6125):1323-8. doi: 10.1126/science.1228792. Epub 2013 Feb 21.

43.

The multifaceted role of mTORC1 in the control of lipid metabolism.

Ricoult SJ, Manning BD.

EMBO Rep. 2013 Mar 1;14(3):242-51. doi: 10.1038/embor.2013.5. Epub 2012 Feb 12. Review.

44.

TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1.

Dibble CC, Elis W, Menon S, Qin W, Klekota J, Asara JM, Finan PM, Kwiatkowski DJ, Murphy LO, Manning BD.

Mol Cell. 2012 Aug 24;47(4):535-46. doi: 10.1016/j.molcel.2012.06.009. Epub 2012 Jul 12.

45.
46.

Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice.

Menon S, Yecies JL, Zhang HH, Howell JJ, Nicholatos J, Harputlugil E, Bronson RT, Kwiatkowski DJ, Manning BD.

Sci Signal. 2012 Mar 27;5(217):ra24. doi: 10.1126/scisignal.2002739.

47.

Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC).

Auricchio N, Malinowska I, Shaw R, Manning BD, Kwiatkowski DJ.

PLoS One. 2012;7(2):e31900. doi: 10.1371/journal.pone.0031900. Epub 2012 Feb 21.

48.

Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, Yong WH, Vinters HV, Gera JF, Cavenee WK, Cloughesy TF, Manning BD, Baldwin AS, Mischel PS.

Cancer Discov. 2011 Nov;1(6):524-38. doi: 10.1158/2159-8290.CD-11-0124. Epub 2011 Sep 13.

49.

Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.

De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, Maertens O, Jeong SM, Bronson RT, Lebleu V, Kalluri R, Normant E, Haigis MC, Manning BD, Wong KK, Macleod KF, Cichowski K.

Cancer Cell. 2011 Sep 13;20(3):400-13. doi: 10.1016/j.ccr.2011.08.014.

50.

Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways.

Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, Lipovsky AI, Gorgun C, Kwiatkowski DJ, Hotamisligil GS, Lee CH, Manning BD.

Cell Metab. 2011 Jul 6;14(1):21-32. doi: 10.1016/j.cmet.2011.06.002. Erratum in: Cell Metab. 2011 Aug 3;14(2):280.

Supplemental Content

Loading ...
Support Center